231 related articles for article (PubMed ID: 26070788)
1. Aldehyde dehydrogenase 1 expression correlates with the invasion of breast cancer.
Pan H; Wu N; Huang Y; Li Q; Liu C; Liang M; Zhou W; Liu X; Wang S
Diagn Pathol; 2015 Jun; 10():66. PubMed ID: 26070788
[TBL] [Abstract][Full Text] [Related]
2. Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study.
Yoshioka T; Umekita Y; Ohi Y; Souda M; Sagara Y; Sagara Y; Sagara Y; Rai Y; Tanimoto A
Histopathology; 2011 Mar; 58(4):608-16. PubMed ID: 21371077
[TBL] [Abstract][Full Text] [Related]
3. Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer.
Ohi Y; Umekita Y; Yoshioka T; Souda M; Rai Y; Sagara Y; Sagara Y; Sagara Y; Tanimoto A
Histopathology; 2011 Oct; 59(4):776-80. PubMed ID: 22014057
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological analysis of breast ductal carcinoma in situ with ALDH1-positive cancer stem cells.
Tsukabe M; Shimazu K; Morimoto K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Kim SJ; Noguchi S
Oncology; 2013; 85(4):248-56. PubMed ID: 24192633
[TBL] [Abstract][Full Text] [Related]
5. EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer.
Knudsen ES; Dervishaj O; Kleer CG; Pajak T; Schwartz GF; Witkiewicz AK
Cell Cycle; 2013 Jul; 12(13):2042-50. PubMed ID: 23759596
[TBL] [Abstract][Full Text] [Related]
6. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
[TBL] [Abstract][Full Text] [Related]
7. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins.
Dzierzanowski M; Melville KA; Barnes PJ; MacIntosh RF; Caines JS; Porter GA
J Surg Oncol; 2005 May; 90(2):71-6. PubMed ID: 15844190
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
10. Proliferation rate and breast cancer subtype, but not ALDH1 expression, predict pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.
Chatterjee D; Bal A; Das A; Singh G
Virchows Arch; 2015 Sep; 467(3):303-10. PubMed ID: 26063415
[TBL] [Abstract][Full Text] [Related]
11. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
[TBL] [Abstract][Full Text] [Related]
12. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
13. Characterization of CD44+ALDH1+Ki-67- Cells in Non-malignant and Neoplastic Lesions of the Breast.
DA Cruz Paula A; Marques O; Sampaio R; Rosa A; Garcia J; Rêma A; DE Fátima Faria M; Silva P; Vizcaíno R; Lopes C
Anticancer Res; 2016 Sep; 36(9):4629-38. PubMed ID: 27630305
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
[TBL] [Abstract][Full Text] [Related]
15. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Oliveira VM; Piato S; Silva MA
Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
[TBL] [Abstract][Full Text] [Related]
16. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.
Morimoto K; Kim SJ; Tanei T; Shimazu K; Tanji Y; Taguchi T; Tamaki Y; Terada N; Noguchi S
Cancer Sci; 2009 Jun; 100(6):1062-8. PubMed ID: 19385968
[TBL] [Abstract][Full Text] [Related]
17. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer.
Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
Neoplasma; 2014; 61(3):352-62. PubMed ID: 24824938
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical study of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinase 1 in benign and malignant breast tissue--strong expression in intraductal carcinomas of the breast.
Rahko E; Kauppila S; Pääkkö P; Blanco G; Apaja-Sarkkinen M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Jukkola A
Tumour Biol; 2009; 30(5-6):257-64. PubMed ID: 19887890
[TBL] [Abstract][Full Text] [Related]
19. Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations.
Wang S; Li W; Lv S; Wang Y; Liu Z; Zhang J; Liu T; Niu Y
Histopathology; 2011 Oct; 59(4):631-42. PubMed ID: 22014044
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer.
Louhichi T; Ziadi S; Saad H; Dhiab MB; Mestiri S; Trimeche M
Breast Cancer; 2018 Nov; 25(6):698-705. PubMed ID: 29845398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
